Lv5
1040 积分 2025-09-05 加入
2024年中国分地区恶性肿瘤流行情况分析
1天前
待确认
First-line benmelstobart plus anlotinib versus sunitinib in advanced renal cell carcinoma (ETER100): a multicentre, randomised, open-label, phase 3 trial
1天前
待确认
舒尼替尼治疗晚期肾癌的预后因素分析及国际转移性肾细胞癌数据库联盟预后模型验证
1天前
待确认
靶向治疗时代转移性肾癌多学科综合治疗的单中心经验总结
1天前
待确认
靶向治疗时代转移性肾癌多学科综合治疗的单中心经验总结
1天前
已关闭
不同部位转移灶对肾癌患者预后的影响及其对IMDC评分的改良价值
1天前
待确认
Prognostic Impact of IMDC Category Shift From Baseline to Nivolumab Initiation in Metastatic Renal Cell Carcinoma: A Sub-Analysis of the MEET-URO 15 Study
1天前
待确认
Prognostic factors for overall survival in patients with metastatic renal cell carcinoma treated with vascular endothelial growth factor-targeted agents: results from a large, multicenter study
1天前
待确认
Postoperative Surveillance for Renal Cell Carcinoma
1天前
已关闭
皖公网安备34019202002308
